Takeda fails to get class decertified in US Amitiza antitrust case
MLex Summary: Takeda Pharmaceuticals was denied a motion to decertify a class of direct purchasers accusing it of delaying a generic version of the drug Amitiza. District Judge Myong J. Joun...To view the full article, register now.
Already a subscriber? Click here to view full article